Molecular Genomics Core

项目总结 分子基因组学核心 分子基因组学核心(MGC)的首要目标是为成员提供复杂的基因组， 对大量和单细胞样本进行转录和表观基因组分析，以支持特殊的高通量 分子、生物学、流行病学和临床科学。MGC是高度集成核心的关键节点 与组织核心(TC)和生物统计学和生物信息学建立无缝实验管道的网络 共享资源(BBSR)。该网络提供全面的覆盖范围，从样本收集到 统计和信息分析，重点是设计高度定制的实验，包括平台 选择和分析方法。这一战略促进了精准医疗的知情实施 满足Moffitt成员研究和临床护理需求的方法。为了支持其目标，MGC 活动分为三个具体目标： 目标一：提供实验设计咨询服务。 目的2：提供高质量的分子基因组学服务。 目标3：提供与基因组学技术进步相关的教育。 在过去的周期中，MGC在所有五个CCSG计划中支持了120名成员，增长了42% 自上次续订以来的使用量，导致101份成员出版物(21份在高影响力期刊上)涵盖 癌症研究领域的广泛主题，包括肿瘤微环境、肿瘤异质性、 治疗的免疫反应、风险分层和循环肿瘤DNA分析。在20财年，支持MGC 所有五个计划的54名成员(CBE 32%、CE 20%、MM 22%、HOB 2%、IO 24%)，其中95% 持有同行评议基金的成员。总体而言，MGC成功地支持了成员的特殊研究 通过高素质和经验丰富的员工，最先进的设施，实验室自动化，广泛的 分子平台，以及推动癌症基因组学领域领先发现的教育和培训。 在未来五年，MGC将通过提供最先进的基因组学和 转录学服务，重点是扩大单细胞测序平台的保留范围，开发 空间基因组技术，以及自动化日常能力，以满足当前和预计的需求 莫菲特会员。为了支持这些努力，MGC还将获得更多平台和更高的吞吐量 仪器仪表。最后，MGC还将扩大其严谨性和再现性倡议，以及其教育和 为会员及其员工提供培训计划。

PROJECT SUMMARY MOLECULAR GENOMICS CORE The overarching goal of the Molecular Genomics Core (MGC) is to provide Members with sophisticated genomic, transcriptomic, and epigenomic analysis of bulk and single cell samples to support exceptional, high throughput molecular, biological, epidemiological, and clinical science. MGC is a critical node of a highly integrated Core network with a seamless experimental pipeline with the Tissue Core (TC) and the Biostatistics & Bioinformatics Shared Resource (BBSR). This network provides comprehensive coverage from sample collection through statistical and informatic analysis, with an emphasis on designing highly tailored experiments, including platform choice and analytical approaches. This strategy facilitates informed implementation of precision medicine approaches to meet the research and clinical care needs of Moffitt Members. In support of its goals, MGC activities are organized into three Specific Aims: Aim 1: To provide experimental design consultation services. Aim 2: To provide high quality molecular genomics services. Aim 3: To provide education related to technological advancements in genomics. Over the past cycle, MGC supported 120 Members across all five CCSG Programs, representing a 42% increase in usage since the last renewal and resulting in 101 Member publications (21 in high impact journals) covering broad topics across the cancer research spectrum, including the tumor microenvironment, tumor heterogeneity, immune response to therapy, risk stratification, and circulating tumor DNA analysis. In FY20, MGC supported 54 Members across all five Programs (CBE 32%, CE 20%, MM 22%, HOB 2%, IO 24%), with 95% of those Members holding peer review funding. Overall, MGC successfully supports exceptional research of Members through a highly qualified and experienced staff, state-of-the-art facilities, laboratory automation, a wide array of molecular platforms, and education and training to drive field-leading discoveries in cancer genomics. Over the next five years, MGC will expand and reinforce its repertoire by providing state-of-the-art genomics and transcriptomics services with a focus on expanding the repertoire of single-cell sequencing platforms, developing spatial genomic technology, and automating routine capabilities to meet the current and projected needs of Moffitt Members. To support these endeavors, MGC will also acquire additional platforms and higher-throughput instrumentation. Finally, MGC will also expand its rigor and reproducibility initiatives, as well as its education and training programs for Members and their staff.